The aim of the study was to analyze the professional literature concerning general principles of medicamental correction for endothelial dysfunction and their peculiarities in patients with chronic obstructive pulmonary disease. The development of chronic obstructive pulmonary disease (COPD) is based on certain trigger factors and pathogenetic processes (chronic inflammation of low intensity, oxidative stress, endothelial dysfunction). These factors are common for a number of other pathological processes, promoting the development of systemic extrapulmonary effects and comorbid conditions. Endothelial dysfunction is of particular interest because it causes, first of all, cardiovascular system pathology. Therefore, modern treatment of COPD, in addition to the drugs approved by clinical protocols, must be supplemented by methods of endothelial dysfunction correction in the long-term management for patients beyond the exacerbation period, which at the same time have no negative effect on the disease course. At present, medicines of various pharmacological groups with a positive effect on the endothelial function are known. Among them are those ones that replenish the deficiency of endothelial relaxing factors or have a direct effect on endothelial receptors; stimulate endothelial nitric oxide synthase activation; prevent endothelial dysfunction caused by mediator influences; regulate the blood coagulation system; provide protection from endothelial cell membrane damage or affect various pathogenetic links of the disease (inflammatory process, immune disorders, dysbiosis, etc.), that indirectly reduces endothelial dysfunction. Conclusions. The key role of endothelial dysfunction in the formation of comorbid pathology in COPD, first of all lesions of cardiovascular system, determines the necessity for complex treatment of these patient groups with additional correction of endothelial dysfunction, especially in long-term management programs beyond the exacerbation period. Given the multifactorial mechanisms of endothelial dysfunction development, the treatment choice for its correction should be personalized taking into account all the disease peculiarities and the comorbid pathology spectrum.
Rehabilitation programs for patients with COPD are based on physical exercises usage, but accounting low tolerance to physical activity, this is not always a real task. The aim is to study the effect of haloaerosoltherapy (HAT) and complex rehabilitation treatment based on it on functional recovery of COPD patients. Materials and methods: 133 patients with COPD (GOLD II-III) beyond acute period were examined. Bronchial obstruction, intensity of clinical manifestations, disturbances of cardiovascular system were investigated. The 6-minute walk test was conducted. Results: Before treatment, it has been shown that exercise tolerance significantly depended on severity of bronchial obstruction, intensity of clinical manifestations and degree of cardiovascular risk. Treatment was carried out according to three treatment complexes (TC). TC-1 was based on HAT usage with certain concentration and dispersion of aerosol, 18-20 seances per course. In TC-2, singlet oxygen therapy was included, in TC-3 mineral water was administered as drinking use and inhalation. After course of treatment, walking distance covered in 6 minutes has been increased in patients of all groups. When using complex treatment, these changes were more pronounced. Con-clusions: HAT with appropriate dispersion and concentration of haloaerosol promotes in-creasing tolerance to physical activity and may be used as a stage of physical rehabilitation with possible subsequent therapeutic physical exercises. Notably pronounced positive dy-namics of studied data was noted in COPD patients convalescents after COVID-19. Key words: COPD, physical rehabilitation, haloaerosoltherapy, COVID-19 convalescents.
Rehabilitation programs for patients with COPD are based on physical exercises usage, but accounting low tolerance to physical activity, this is not always a real task. The aim is to study the effect of haloaerosoltherapy (HAT) and complex rehabilitation treatment based on it on functional recovery of COPD patients. Materials and methods: 133 patients with COPD (GOLD II-III) beyond acute period were examined. Bronchial obstruction, intensity of clinical manifestations, disturbances of cardiovascular system were investigated. The 6-minute walk test was conducted. Results: Before treatment, it has been shown that exercise tolerance significantly depended on severity of bronchial obstruction, intensity of clinical manifestations and degree of cardiovascular risk. Treatment was carried out according to three treatment complexes (TC). TC-1 was based on HAT usage with certain concentration and dispersion of aerosol, 18-20 seances per course. In TC-2, singlet oxygen therapy was included, in TC-3 mineral water was administered as drinking use and inhalation. After course of treatment, walking distance covered in 6 minutes has been increased in patients of all groups. When using complex treatment, these changes were more pronounced. Con-clusions: HAT with appropriate dispersion and concentration of haloaerosol promotes in-creasing tolerance to physical activity and may be used as a stage of physical rehabilitation with possible subsequent therapeutic physical exercises. Notably pronounced positive dy-namics of studied data was noted in COPD patients convalescents after COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.